Company / Return on Equity (ROE)
Cartesian Therapeutics, Inc. Return on Equity (ROE) History
FY2019-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Equity (ROE)
-27.4%
FY2023
5-year range
-659.2% / -27.4%
FY2019-FY2023
Trend
-
vs FY2022
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Cartesian Therapeutics, Inc. reports negative total equity of -27.4% in FY2023. Negative equity can occur when accumulated losses exceed contributed capital, as reported in the balance sheet from the SEC filing.
Based on SEC 10-K filings.
-27.4% in FY2023.
Improved from -126.1% to -27.4% over the past 4 years.
Return on Equity (ROE) over time
Growth rates
- 3-Year Change
- -
- 5-Year Change
- -
- 10-Year Change
- -
Company context
Key Data Points
- Altman Z-Score -0.06 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Equity (ROE)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | -27.4% | - |
| FY2022 | - | - |
| FY2021 | -659.2% | - |
| FY2020 | - | - |
| FY2019 | -126.1% | - |
| FY2016 | - | - |
As of FY2023 · SEC 10-K · Updated Jun 28, 2026